WO2005097134A3 - Quinazoline based protein kinase inhibitors - Google Patents
Quinazoline based protein kinase inhibitorsInfo
- Publication number
- WO2005097134A3 WO2005097134A3 PCT/US2005/010968 US2005010968W WO2005097134A3 WO 2005097134 A3 WO2005097134 A3 WO 2005097134A3 US 2005010968 W US2005010968 W US 2005010968W WO 2005097134 A3 WO2005097134 A3 WO 2005097134A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein kinase
- kinase inhibitors
- based protein
- quinazoline based
- quinazoline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55802504P | 2004-03-31 | 2004-03-31 | |
US60/558,025 | 2004-03-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005097134A2 WO2005097134A2 (en) | 2005-10-20 |
WO2005097134A3 true WO2005097134A3 (en) | 2006-01-26 |
Family
ID=35125608
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/010974 WO2005097137A2 (en) | 2004-03-31 | 2005-03-31 | Advanced quinazoline based protein kinase inhibitors |
PCT/US2005/010968 WO2005097134A2 (en) | 2004-03-31 | 2005-03-31 | Quinazoline based protein kinase inhibitors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/010974 WO2005097137A2 (en) | 2004-03-31 | 2005-03-31 | Advanced quinazoline based protein kinase inhibitors |
Country Status (1)
Country | Link |
---|---|
WO (2) | WO2005097137A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9353123B2 (en) | 2013-02-20 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US9353122B2 (en) | 2013-02-15 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0509227D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
GB0509224D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of intracellular enzymatic activity |
EP1940825A1 (en) * | 2005-09-20 | 2008-07-09 | Astra Zeneca AB | Quinazoline derivatives as anticancer agents |
WO2007063291A1 (en) * | 2005-12-02 | 2007-06-07 | Astrazeneca Ab | 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors |
CN101003514A (en) * | 2006-01-20 | 2007-07-25 | 上海艾力斯医药科技有限公司 | Derivative of quinazoline, preparation method and usage |
SG174772A1 (en) * | 2006-09-11 | 2011-10-28 | Curis Inc | Multi-functional small molecules as anti-proliferative agents |
US7977347B2 (en) * | 2006-09-11 | 2011-07-12 | Curis, Inc. | Quinazoline based EGFR inhibitors |
AU2012216752B2 (en) * | 2006-09-11 | 2014-12-04 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
WO2008033749A2 (en) * | 2006-09-11 | 2008-03-20 | Curis, Inc. | Quinazoline based egfr inhibitors containing a zinc binding moiety |
US7851623B2 (en) | 2006-11-02 | 2010-12-14 | Astrazeneca Ab | Chemical process |
US8148532B2 (en) | 2007-03-14 | 2012-04-03 | Guoqing Paul Chen | Spiro substituted compounds as angiogenesis inhibitors |
US8119616B2 (en) | 2007-09-10 | 2012-02-21 | Curis, Inc. | Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety |
ES2526718T3 (en) | 2007-09-10 | 2015-01-14 | Curis, Inc. | EGFR inhibitors based on tartrate salts or quinazoline complexes containing a moiety that binds zinc |
US7829574B2 (en) * | 2008-05-09 | 2010-11-09 | Hutchison Medipharma Enterprises Limited | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
US8211911B2 (en) | 2008-08-19 | 2012-07-03 | Guoqing Paul Chen | Compounds as kinase inhibitors |
WO2011056957A2 (en) * | 2009-11-06 | 2011-05-12 | Chelsea Therapeutics, Inc. | Enzyme inhibiting compounds |
CN101857617A (en) * | 2010-04-28 | 2010-10-13 | 中国海洋大学 | Quinazoline sugar derivative and preparation method and application thereof |
CN102452988B (en) * | 2010-10-27 | 2016-01-27 | 中国科学院化学研究所 | A kind of quinazoline derivant and preparation method thereof |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
KR101645112B1 (en) | 2013-03-06 | 2016-08-02 | 아스트라제네카 아베 | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor |
AU2014342042B2 (en) | 2013-11-01 | 2017-08-17 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
CN104761507B (en) * | 2014-01-06 | 2019-11-12 | 广东东阳光药业有限公司 | Amido quinazoline derivatives and its application in drug |
CN105384745A (en) * | 2015-07-27 | 2016-03-09 | 北京师范大学 | Crown ether cyclic quinazoline compound, preparation method therefor and application thereof in preparing tumor therapy and imaging drug |
US10392399B2 (en) | 2016-09-08 | 2019-08-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
CA3036336A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
BR112019004463A2 (en) | 2016-09-08 | 2019-05-28 | Kala Pharmaceuticals Inc | crystalline forms of therapeutic compounds, their processes for obtaining and their methods of use |
CN110357858B (en) | 2018-04-09 | 2022-02-18 | 威尚(上海)生物医药有限公司 | 5-substituted difluoropiperidine compounds having blood-brain barrier crossing capability |
EP3778589B1 (en) * | 2018-04-09 | 2022-05-11 | Weishang (Shanghai) Bio-Pharmaceutical Co., Ltd. | 5-substituted difluoropiperidine compound capable of passing through blood-brain barrier |
CN110590839B (en) * | 2018-06-13 | 2022-04-05 | 四川海思科制药有限公司 | Levatinib derivative and preparation method and application thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5362743A (en) * | 1993-03-09 | 1994-11-08 | Pfizer Inc. | Aminoquinoline derivatives |
US5492915A (en) * | 1990-07-24 | 1996-02-20 | Rhone-Poulenc Rorer S.A. | Substituted quinolyl compounds exhibiting selective leukotriene B4 antagonist activity |
WO1996033980A1 (en) * | 1995-04-27 | 1996-10-31 | Zeneca Limited | Quinazoline derivatives |
US6169088B1 (en) * | 1996-01-10 | 2001-01-02 | Kyowa Hakko Kogyo Co., Ltd. | 1,3 diazines with platelet-derived growth factor receptor inhibitory activity |
US20020091130A1 (en) * | 2000-11-01 | 2002-07-11 | James Kanter | Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof |
-
2005
- 2005-03-31 WO PCT/US2005/010974 patent/WO2005097137A2/en active Application Filing
- 2005-03-31 WO PCT/US2005/010968 patent/WO2005097134A2/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5492915A (en) * | 1990-07-24 | 1996-02-20 | Rhone-Poulenc Rorer S.A. | Substituted quinolyl compounds exhibiting selective leukotriene B4 antagonist activity |
US5362743A (en) * | 1993-03-09 | 1994-11-08 | Pfizer Inc. | Aminoquinoline derivatives |
WO1996033980A1 (en) * | 1995-04-27 | 1996-10-31 | Zeneca Limited | Quinazoline derivatives |
US5770599A (en) * | 1995-04-27 | 1998-06-23 | Zeneca Limited | Quinazoline derivatives |
US6169088B1 (en) * | 1996-01-10 | 2001-01-02 | Kyowa Hakko Kogyo Co., Ltd. | 1,3 diazines with platelet-derived growth factor receptor inhibitory activity |
US20020091130A1 (en) * | 2000-11-01 | 2002-07-11 | James Kanter | Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9353122B2 (en) | 2013-02-15 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US9353123B2 (en) | 2013-02-20 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2005097137A3 (en) | 2006-02-16 |
WO2005097137A2 (en) | 2005-10-20 |
WO2005097134A2 (en) | 2005-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005097134A3 (en) | Quinazoline based protein kinase inhibitors | |
WO2008083367A3 (en) | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors | |
WO2007030680A3 (en) | Triazole derivatives useful as axl inhibitors | |
WO2008033748A3 (en) | Quinazoline based egfr inhibitors containing a zinc binding moiety | |
EP2476679A3 (en) | Substituted triazoles useful as AXL inhibitors | |
WO2008033749A3 (en) | Quinazoline based egfr inhibitors containing a zinc binding moiety | |
WO2008033746A3 (en) | Tyrosine kinase inhibitors containing a zinc binding moiety | |
WO2008080134A3 (en) | 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors | |
HK1116349A1 (en) | Pyrrolopyrimidines useful as inhibitors of protein kinase | |
WO2010005876A3 (en) | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors | |
WO2006069080A3 (en) | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2m3-b]pyrimidin-4-yl-amines as janus kinase inhibitors | |
WO2007056163A3 (en) | Aminopyrimidines useful as kinase inhibitors | |
WO2008115973A3 (en) | Aminopyrimidines useful as kinase inhibitors | |
EP2484679A3 (en) | N3-heteroaryl substituted triazoles and n5-heteroaryl substitued triazoles useful as axl inhibitors | |
WO2006031806A3 (en) | 2-thiopyrimidinones as therapeutic agents | |
WO2007067781A3 (en) | 9-membered heterobicyclic compounds as inhibitors of protein kinases | |
MX2009009117A (en) | Pyrimidine-2,4-diamine derivatives and their use as jak2 kinase inhibitors. | |
WO2008033745A3 (en) | Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety | |
TW200630090A (en) | Triazoles useful as inhibitors of protein kinases | |
WO2008137622A3 (en) | Aminopyrimidines useful as kinase inhibitors | |
MX2009004771A (en) | Tricyclic heteroaryl compounds useful as inhibitors of janus kinase. | |
WO2012048259A3 (en) | Substituted pyridazine carboxamide compounds | |
WO2007081901A3 (en) | Pyrimidinone derivatives as protein kinase inhibitors | |
IL179206A0 (en) | Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same | |
WO2005053614A3 (en) | Advanced indolinone based protein kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |